GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (OTCPK:CLVLF) » Definitions » 12-1 Month Momentum %

CLVLF (Clinuvel Pharmaceuticals) 12-1 Month Momentum % : -17.49% (As of Dec. 15, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-12-15), Clinuvel Pharmaceuticals's 12-1 Month Momentum % is -17.49%.

The industry rank for Clinuvel Pharmaceuticals's 12-1 Month Momentum % or its related term are showing as below:

CLVLF's 12-1 Month Momentum % is ranked worse than
50.24% of 1447 companies
in the Biotechnology industry
Industry Median: -15.46 vs CLVLF: -17.49

Competitive Comparison of Clinuvel Pharmaceuticals's 12-1 Month Momentum %

For the Biotechnology subindustry, Clinuvel Pharmaceuticals's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clinuvel Pharmaceuticals's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Clinuvel Pharmaceuticals's 12-1 Month Momentum % falls into.



Clinuvel Pharmaceuticals  (OTCPK:CLVLF) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clinuvel Pharmaceuticals  (OTCPK:CLVLF) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Clinuvel Pharmaceuticals 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Clinuvel Pharmaceuticals Business Description

Address
535 Bourke Street, Level 22, Melbourne, VIC, AUS, 3000
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.

Clinuvel Pharmaceuticals Headlines

From GuruFocus

Letter to shareholders from CLINUVEL's CEO

By GuruFocusNews GuruFocusNews 04-29-2022

Positive final results in stroke

By GuruFocusNews GuruFocusNews 05-04-2022

CLINUVEL Launches CYAC�LLE, Next Generation Solar Care

By sperokesalga sperokesalga 03-01-2023

CLINUVEL to Trial Innovative Drug in Stroke

By Marketwired Marketwired 10-28-2020

PRÉNUMBRA® - CLINUVEL's Second Afamelanotide Formulation

By Marketwired Marketwired 07-13-2020

CLINUVEL Trial Results Show Drug Reduces DNA Damage

By Stock market mentor Stock market mentor 01-16-2023